U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SEC File No.: 0-109659
Form 12b-25
Notification of Late Filing
(Check One):
[ ] Form 10-KSB [ ] Form 11-K [ ] Form 20-F
[ X ] Form 10-QSB [ ] Form N-SAR
For Period Ended: September 30, 2000
--------------------------------------------------------------------------------
Nothing in this Form shall be construed to imply that the Commission has
verified any information contained herein.
--------------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates: N/A
--------------------------------------------------------------------------------
Part I-Registration Information
--------------------------------------------------------------------------------
Full Name of Registrant: Cita Biomedical, Inc.
Former Name if Applicable: N/A
9025 Wilshire Blvd, Suite 301
Address of Principal Executive Office (Street and Number)
Beverly Hills, CA 90211
City, State and Zip Code
<PAGE>
--------------------------------------------------------------------------------
Part II-Rules 12b-25 (b) and (c)
--------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25 (b), the following
should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report or semi-annual report/portion thereof
will be filed on or before the fifteenth calendar day following
the prescribed due date: or the subject quarterly report/portion
thereof will be filed on or before the fifth calendar day
following the prescribed due date and;
[X] (c) The accountant's statement or other exhibit required by
Rule 12-b-25 (c) has been attached if applicable.
--------------------------------------------------------------------------------
Part III - Narrative
--------------------------------------------------------------------------------
State below in reasonable detail the reasons why the form 10-KSB, 11-K, 20-K,
10-QSB or N-SAR or portion thereof could not be filed within the prescribed time
period.
The accountants have only recently completed the accruals and adjustments
necessary for the financial statements. Because of the delay in completing these
adjustments, the Registrant does not have sufficient time to meet filing
requirements for Form 10-QSB and to complete the financial/accounting
requirements by the due date.
--------------------------------------------------------------------------------
Part IV-Other Information
--------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification.
Sam Cordovano (303) 329-0220
-----------------------------------------------------------------------
(Name) (Area Code) Telephone Number
(2) Have all other periodic reports required under section 30 of the
Securities Exchange Act of 1934 or section 30 of Investment Company Act
of 1940 during the proceeding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If the
answer is no, identify report(s). [ X ] Yes [ ] No
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof? [ ]Yes [X ] No If so: attach an explanation
of the anticipated change both narratively and quantitatively, and, if
appropriate, state the reasons why a reasonable estimate of the results
cannot be made.
CITA BIOMEDICAL, INC., has caused this notification to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: November 14, 2000 By: /s/ Joseph Dunn
-------------------------
Joseph Dunn
President, CEO, CFO
